Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus LORATADINE REDIDOSE.
HISTAFED vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
10 mg orally once daily
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine